Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
COVID-19
Biotech
BioNTech pays $200M to license OncoC4's mid-stage antibody
BioNTech is paying $200 million upfront to license OncoC4's monoclonal antibody aimed at solid tumors, furthering the former's clinical cancer work.
Max Bayer
Mar 20, 2023 11:15am
Immunome decides not to top up its COVID antibody cocktail
Mar 16, 2023 10:05am
Vaxart cans oral COVID-19 vaccine plans, lays off 27% of staff
Mar 16, 2023 6:15am
FDA defends delayed EUA for Lucira's combo COVID/flu test
Mar 13, 2023 10:13am
FDA issues first full clearance for a rapid antigen COVID test
Mar 9, 2023 11:04am
Invivyd evolves yet again to keep pace with COVID-19
Mar 6, 2023 10:45am
More News
Veru's EUA ambitions for its COVID treatment crash
Mar 3, 2023 11:17am
FDA issues first EUA to over-the-counter COVID and flu test
Feb 27, 2023 10:01am
'We beg you': Biotechs plead for help with long COVID research
Feb 22, 2023 11:20am
Medtronic slows sales slip with flat revenues in Q3
Feb 21, 2023 3:05pm
See more stories